Diabetes, Vol 48, Issue 4 706-713, Copyright © 1999 by American Diabetes Association

ARTICLES

Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes

M Flodstrom, B Tyrberg, DL Eizirik and S Sandler
Department of Medical Cell Biology, Uppsala University, Sweden. malinf@scripps.edu

Nitric oxide (NO), synthesized by the inducible isoform of nitric oxide synthase (iNOS), has been proposed as a mediator of immune-induced beta-cell destruction in type 1 diabetes. To evaluate the role of iNOS for beta-cell dysfunction and death, we investigated the sensitivity of beta-cells from mice genetically deficient in this enzyme (iNOS-/-, background C57BL/6x129SvEv, H-2b) both to interleukin (IL)-1beta-induced beta-cell dysfunction in vitro and to multiple low-dose streptozotocin (MLDS)-induced diabetes in vivo. Exposure of islets isolated from C57BL/6 mice to IL-1beta for 24 h in vitro resulted in an induction of iNOS mRNA expression, an increase in nitrite formation, and a decrease in insulin release and proinsulin biosynthesis as compared with untreated C57BL/6 islets. IL-1beta failed to induce iNOS mRNA expression and increase nitrite formation by islets isolated from iNOS knockout mice (iNOS-/-), and no impairment in islet function was observed. The iNOS-/- mice showed a reduced incidence of hyperglycemia after treatment with MLDS as compared with wild-type C57BL/6 (H-2b) and 129 SvEv (H-2b) mice. On day 21 after the first streptozotocin (STZ) injection, 75% of the C57BL/6 mice and 100% of the 129SvEv mice had blood glucose levels >11 mmol/l, whereas the corresponding number for iNOS-/- mice was only 23%. This protection was not due to a delay in the onset of hyperglycemia, since no increase in number of hyperglycemic iNOS-/- mice was observed when the animals were followed up to 42 days. Moreover, islets isolated from iNOS-/- mice were susceptible to the in vitro deleterious effects of STZ. In conclusion, the present study provides evidence that iNOS may contribute to beta-cell damage after exposure to IL-1beta in vitro and treatment with MLDS in vivo.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Y. Savinov, D. V. Rozanov, and A. Y. Strongin Specific Inhibition of Autoimmune T Cell Transmigration Contributes to beta Cell Functionality and Insulin Synthesis in Non-obese Diabetic (NOD) Mice J. Biol. Chem., November 2, 2007; 282(44): 32106 - 32111. [Abstract] [Full Text] [PDF]

				A. P. Martin, J. M. Alexander-Brett, C. Canasto-Chibuque, A. Garin, J. S. Bromberg, D. H. Fremont, and S. A. Lira The Chemokine Binding Protein M3 Prevents Diabetes Induced by Multiple Low Doses of Streptozotocin J. Immunol., April 1, 2007; 178(7): 4623 - 4631. [Abstract] [Full Text] [PDF]

				S. Stosic-Grujicic, I. Cvetkovic, K. Mangano, M. Fresta, D. Maksimovic-Ivanic, L. Harhaji, D. Popadic, M. Momcilovic, D. Miljkovic, J. Kim, et al. A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1038 - 1049. [Abstract] [Full Text] [PDF]

				P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF]

				B. Pozo-Navas, H. Stessel, G. Wolkart, and F. Brunner Role of Myocardial Nitric Oxide in Diabetic Ischemia-Reperfusion Dysfunction: Studies in Mice with Myocyte-Specific Overexpression of Endothelial Nitric-Oxide Synthase J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 729 - 738. [Abstract] [Full Text] [PDF]

				M. Kitazawa, Y. Shibata, S. Hashimoto, Y. Ohizumi, and T. Yamakuni Proinsulin C-Peptide Stimulates a PKC/I{kappa}B/NF-{kappa}B Signaling Pathway to Activate COX-2 Gene Transcription in Swiss 3T3 Fibroblasts J. Biochem., June 1, 2006; 139(6): 1083 - 1088. [Abstract] [Full Text] [PDF]

				T. Rydgren, D. Bengtsson, and S. Sandler Complete Protection Against Interleukin-1{beta}-Induced Functional Suppression and Cytokine-Mediated Cytotoxicity in Rat Pancreatic Islets In Vitro Using an Interleukin-1 Cytokine Trap. Diabetes, May 1, 2006; 55(5): 1407 - 1412. [Abstract] [Full Text] [PDF]

				R. Eldor, A. Yeffet, K. Baum, V. Doviner, D. Amar, Y. Ben-Neriah, G. Christofori, A. Peled, J. C. Carel, C. Boitard, et al. Conditional and specific NF-{kappa}B blockade protects pancreatic beta cells from diabetogenic agents PNAS, March 28, 2006; 103(13): 5072 - 5077. [Abstract] [Full Text] [PDF]

				H. Wang, S. S. Lee, C. Dell'Agnello, V. Tchipashvili, J. D'Avilla, E. Czismadia, B. Y. Chin, and F. H. Bach Bilirubin Can Induce Tolerance to Islet Allografts Endocrinology, February 1, 2006; 147(2): 762 - 768. [Abstract] [Full Text] [PDF]

				J. M. Kennedy and D. W. Zochodne Experimental Diabetic Neuropathy With Spontaneous Recovery: Is There Irreparable Damage? Diabetes, March 1, 2005; 54(3): 830 - 837. [Abstract] [Full Text] [PDF]

				M. R. Heitmeier, C. B. Kelly, N. J. Ensor, K. A. Gibson, K. G. Mullis, J. A. Corbett, and T. J. Maziasz Role of Cyclooxygenase-2 in Cytokine-induced {beta}-Cell Dysfunction and Damage by Isolated Rat and Human Islets J. Biol. Chem., December 17, 2004; 279(51): 53145 - 53151. [Abstract] [Full Text] [PDF]

				M. G. Hartman, D. Lu, M.-L. Kim, G. J. Kociba, T. Shukri, J. Buteau, X. Wang, W. L. Frankel, D. Guttridge, M. Prentki, et al. Role for Activating Transcription Factor 3 in Stress-Induced {beta}-Cell Apoptosis Mol. Cell. Biol., July 1, 2004; 24(13): 5721 - 5732. [Abstract] [Full Text] [PDF]

				M. I. Darville, S. Terryn, and D. L. Eizirik An Octamer Motif Is Required for Activation of the Inducible Nitric Oxide Synthase Promoter in Pancreatic {beta}-Cells Endocrinology, March 1, 2004; 145(3): 1130 - 1136. [Abstract] [Full Text] [PDF]

				S. Ramanadham, H. Song, S. Bao, F.-F. Hsu, S. Zhang, Z. Ma, C. Jin, and J. Turk Islet Complex Lipids: Involvement in the Actions of Group VIA Calcium-Independent Phospholipase A2 in {beta}-Cells Diabetes, February 1, 2004; 53(90001): S179 - 185. [Abstract] [Full Text]

				W. H. Schott, B. D. Haskell, H. M. Tse, M. J. Milton, J. D. Piganelli, C. M. Choisy-Rossi, P. C. Reifsnyder, A. V. Chervonsky, and E. H. Leiter Caspase-1 Is Not Required for Type 1 Diabetes in the NOD Mouse Diabetes, January 1, 2004; 53(1): 99 - 104. [Abstract] [Full Text] [PDF]

				C. A. Gunnett, D. D. Heistad, and F. M. Faraci Gene-Targeted Mice Reveal a Critical Role for Inducible Nitric Oxide Synthase in Vascular Dysfunction During Diabetes Stroke, December 1, 2003; 34(12): 2970 - 2974. [Abstract] [Full Text] [PDF]

				M. Flodstrom-Tullberg, D. Yadav, R. Hagerkvist, D. Tsai, P. Secrest, A. Stotland, and N. Sarvetnick Target Cell Expression of Suppressor of Cytokine Signaling-1 Prevents Diabetes in the NOD Mouse Diabetes, November 1, 2003; 52(11): 2696 - 2700. [Abstract] [Full Text] [PDF]

				M. Flodstrom, D. Tsai, C. Fine, A. Maday, and N. Sarvetnick Diabetogenic Potential of Human Pathogens Uncovered in Experimentally Permissive {beta}-Cells Diabetes, August 1, 2003; 52(8): 2025 - 2034. [Abstract] [Full Text] [PDF]

				A. L. Scarim, S. Y. Nishimoto, S. M. Weber, and J. A. Corbett Role for c-Jun N-Terminal Kinase in {beta}-Cell Recovery from Nitric Oxide-Mediated Damage Endocrinology, August 1, 2003; 144(8): 3415 - 3422. [Abstract] [Full Text] [PDF]

				V. V. Tran, G. Chen, C. B. Newgard, and H. E. Hohmeier Discrete and Complementary Mechanisms of Protection of {beta}-Cells Against Cytokine-Induced and Oxidative Damage Achieved by bcl-2 Overexpression and a Cytokine Selection Strategy Diabetes, June 1, 2003; 52(6): 1423 - 1432. [Abstract] [Full Text] [PDF]

				S. M. Weber, A. L. Scarim, and J. A. Corbett Inhibition of IFN-gamma -induced STAT1 activation by 15- deoxy-Delta 12,14-prostaglandin J2 Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E883 - E891. [Abstract] [Full Text] [PDF]

				R. D. Hoeldtke, K. D. Bryner, D. R. McNeill, S. S. Warehime, K. Van Dyke, and G. Hobbs Oxidative Stress and Insulin Requirements in Patients with Recent-Onset Type 1 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1624 - 1628. [Abstract] [Full Text] [PDF]

				L. Virag and C. Szabo The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors Pharmacol. Rev., September 1, 2002; 54(3): 375 - 429. [Abstract] [Full Text] [PDF]

				J. G. Mabley, P. Pacher, G. J. Southan, A. L. Salzman, and C. Szabo Nicotine Reduces the Incidence of Type I Diabetes in Mice J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 876 - 881. [Abstract] [Full Text] [PDF]

				H. E. Thomas, R. Darwiche, J. A. Corbett, and T. W.H. Kay Interleukin-1 Plus {gamma}-Interferon-Induced Pancreatic {beta}-Cell Dysfunction Is Mediated by {beta}-Cell Nitric Oxide Production Diabetes, February 1, 2002; 51(2): 311 - 316. [Abstract] [Full Text] [PDF]

				P.-O. Carlsson, M. Flodstrom, and S. Sandler Islet Blood Flow in Multiple Low Dose Streptozotocin-Treated Wild-Type and Inducible Nitric Oxide Synthase-Deficient Mice Endocrinology, August 1, 2000; 141(8): 2752 - 2757. [Abstract] [Full Text] [PDF]

				M.-C. Chen, V. Paez-Espinosa, N. Welsh, and D. L. Eizirik Interleukin-1{beta} Regulates Phospholipase D-1 Expression in Rat Pancreatic {beta}-Cells Endocrinology, August 1, 2000; 141(8): 2822 - 2828. [Abstract] [Full Text] [PDF]

				E. Ho and T. M. Bray Antioxidants, NF{kappa}B Activation, and Diabetogenesis Experimental Biology and Medicine, December 1, 1999; 222(3): 205 - 213. [Abstract] [Full Text]

				C. Bonny, A. Oberson, M. Steinmann, D. F. Schorderet, P. Nicod, and G. Waeber IB1 Reduces Cytokine-induced Apoptosis of Insulin-secreting Cells J. Biol. Chem., May 26, 2000; 275(22): 16466 - 16472. [Abstract] [Full Text] [PDF]